STOCK TITAN
  1. Home
  2. News
  3. OPK

Opko Health Inc. - OPK STOCK NEWS

Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.

OPKO Health Inc. (NASDAQ: OPK) is a diversified healthcare company focused on establishing leading positions in large, rapidly growing markets. OPKO operates through two main segments: Diagnostics and Pharmaceuticals.

OPKO's Diagnostics segment includes BioReference Laboratories, the nation's third largest clinical laboratory. BioReference offers a comprehensive range of diagnostic services and features a core genetic testing business supported by a skilled 400-person sales and marketing team. Notable products include the 4Kscore® test for prostate cancer and the Claros® 1 in-office immunoassay platform.

The Pharmaceutical segment of OPKO showcases a diverse portfolio of products. Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency, was launched in November 2016. Other significant pharmaceutical developments include Varubitm for chemotherapy-induced nausea and vomiting, OPK88004 for type 2 diabetes and obesity, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia, both of which are in Phase 2 clinical trials.

OPKO has recently made headlines with strategic collaborations and technological advancements. BioReference Health, a subsidiary of OPKO, has entered a strategic alliance with SOPHiA GENETICS to incorporate MSK-ACCESS® liquid biopsy technology. This partnership aims to enhance BioReference's genomic analysis capabilities and offer state-of-the-art cancer testing across the U.S. Another collaboration with Prognos Health aims to merge genomic data with real-world data, facilitating precision medicine and improving patient outcomes.

Financially, OPKO continues to exhibit a strong performance with ongoing projects and strategic acquisitions. The acquisition of select assets from BioReference Health by Labcorp is set to expand OPKO's reach and capabilities, strengthening its market presence.

Headquartered in Miami, Florida, OPKO Health is committed to improving healthcare through innovation, scientific expertise, and strategic partnerships. For more detailed information about their products, services, and latest news, visit www.opko.com.

News

OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
OPKO Health, Inc. (OPK) to participate in the 42nd Annual J.P. Morgan Healthcare Conference, hosting one-on-one meetings with investors and presenting on January 10th. The presentation will be webcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.36%
Tags
conferences
-
News

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029. The Notes will bear interest at a rate of 3.75% per annum, payable semiannually, and will mature on January 15, 2029. The Company also entered into separate, privately negotiated transactions to repurchase approximately $144.4 million aggregate principal amount of its outstanding 4.50% Convertible Senior Notes due 2025. The net proceeds from the offering will be approximately $192.5 million, with approximately $50.0 million to be used for repurchasing shares of common stock from purchasers of Notes in privately negotiated transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
offering
-
News

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) announces private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 with the option to purchase an additional $30.0 million. The Company expects to use the proceeds for repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.33%
Tags
offering
News

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Rhea-AI Summary
BioReference Health, LLC (BRH) has announced a strategic collaboration with Prognos Health to offer unique solutions for healthcare providers and researchers. The partnership aims to combine genetic data and critical biomarkers to provide targeted precision therapies based on patients' genetic profiles. This collaboration will utilize Prognos Health's managed real world data marketplace, which contains over 325 million de-identified patient health records, to accelerate the development and delivery of innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Rhea-AI Summary
SOPHiA GENETICS announced that BioReference Health, LLC will implement its technology and add MSK-ACCESS liquid biopsy to its test suite, making it the first laboratory globally to adopt this technology. The offering will be commercially available for ordering by healthcare providers through BioReference and its specialty division, GenPath Oncology, in 2024. The new liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Rhea-AI Summary
OPKO Health, Inc. reports business highlights and financial results for the third quarter of 2023. ModeX Therapeutics awarded a $59 million contract from BARDA for the development of multispecific antibodies against viral infectious diseases. NGENLA approved in 48 markets, sales underway in 23 countries. New clinical data on RAYALDEE® presented at Kidney Week 2023. OPKO Biologics enters research collaboration agreement with Entera Bio Ltd. for oral peptide tablet formulations. BioReference Health implementing initiatives to return to profitability. Consolidated total revenues for Q3 2023 were $178.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Rhea-AI Summary
OPKO Health presented clinical data on RAYALDEE at the American Society of Nephrology Kidney Week. The data show that early and effective treatment of secondary hyperparathyroidism with RAYALDEE is associated with slower progression of chronic kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
clinical trial
-
News

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) will report its operating and financial results for the three and nine months ended September 30, 2023 on November 6, 2023. The company's senior management will provide a business update and discuss results during a conference call and live webcast. Participants can pre-register for the conference call to receive a unique PIN for immediate access. The call can be accessed via phone or webcast, and replays will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences earnings
News

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Rhea-AI Summary
OPKO Health to present late-breaking clinical data on RAYALDEE at ASN Kidney Week
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences clinical trial

FAQ

What is the current stock price of Opko Health (OPK)?

The current stock price of Opko Health (OPK) is $1.54 as of December 20, 2024.

What is the market cap of Opko Health (OPK)?

The market cap of Opko Health (OPK) is approximately 1.0B.

What does OPKO Health Inc. specialize in?

OPKO Health Inc. specializes in diagnostics and pharmaceuticals, focusing on genetic testing and treatments for chronic diseases.

What are the main products offered by OPKO Health?

Key products include the 4Kscore® prostate cancer test, Rayaldee for secondary hyperparathyroidism, and Varubitm for chemotherapy-induced nausea.

What recent collaborations has OPKO Health announced?

OPKO Health's BioReference Health has partnered with SOPHiA GENETICS for genomic analysis and Prognos Health for real-world data integration.

Where is OPKO Health headquartered?

OPKO Health is headquartered in Miami, Florida.

What is the significance of the 4Kscore® test?

The 4Kscore® test is a blood test that helps assess the risk of aggressive prostate cancer, aiding in early detection and treatment planning.

How does BioReference Laboratories fit into OPKO Health's operations?

BioReference Laboratories is a key component of OPKO's diagnostics segment, offering comprehensive clinical and genetic testing services.

What is Rayaldee used for?

Rayaldee is used to treat secondary hyperparathyroidism in patients with stage 3-4 chronic kidney disease and vitamin D insufficiency.

What impact will the Labcorp acquisition have on OPKO Health?

The acquisition will expand OPKO's capabilities and market reach, enhancing its diagnostic services and overall market presence.

What are the future goals of OPKO Health?

OPKO aims to establish industry-leading positions in rapidly growing markets by leveraging its innovative technologies and strategic partnerships.

How can investors learn more about OPKO Health's performance?

Investors can visit OPKO's official website at www.opko.com for detailed information on financial performance, product updates, and strategic initiatives.

Stock OPK logo
Opko Health Inc.

Nasdaq:OPK

OPK Rankings

#2509 Ranked by Market Cap
N/A Ranked by Dividends

OPK Stock Data

1.03B
301.07M
54.47%
28.03%
14.22%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
MIAMI